ESSB 5916
In CommitteeSenate
Nonopioid drugs for pain
Concerning nonopioid drugs for the treatment of pain.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill requires health plans in Washington to cover nonopioid pain medications as fairly as opioid medications—no higher costs, extra paperwork, or stricter rules for nonopioids. It also requires the state to create a public education guide about nonopioid pain treatments. The rules take effect starting January 1, 2027.
- Health plans (including state employee plans, private insurance, and Medicaid-managed care) must cover nonopioid pain drugs at the same or better level as opioid drugs—no higher copays, fewer prior authorization steps, or less favorable coverage tiers.
- Plans may not label nonopioid drugs as ‘nonpreferred’ if any opioid is labeled ‘preferred’—ensuring equal access to nonopioid options.
- Plans must apply the same or less restrictive rules (like prior authorization or step therapy) to nonopioid drugs as they do to opioids.
- The Washington State Department of Health must create and post an educational pamphlet by January 1, 2027, explaining nonopioid pain treatment options—including medications and non-drug therapies—and their pros and cons.
- Definitions in existing law are updated to clarify terms like ‘nonopioid drug’, ‘prior authorization’, and ‘step therapy’ to support consistent application of the new rules.
Who is affected
- State employees and their dependents — Employees and dependents covered under state-sponsored health plans will have better access to nonopioid pain treatments, as their health plans will be required to cover these drugs without extra barriers like extra paperwork or higher costs compared to opioids.
- Health plan members (including Medicaid recipients) — Residents enrolled in private or public health plans (including Medicaid-managed care) will benefit from more equitable coverage of nonopioid pain medications, making safer alternatives easier to access.
- Health care providers — Health care providers (doctors, nurses, pharmacists) will need to follow new rules when prescribing or dispensing pain medications and may need to use standardized, less restrictive processes for nonopioid drugs.
- Health insurers and managed care organizations — Health insurers, pharmacy benefit managers, and managed care organizations must revise their drug coverage rules to ensure nonopioid pain drugs are not treated less favorably than opioids.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Reduces financial and administrative barriers to nonopioid pain treatments—especially important for low-income patients, seniors on fixed incomes, and those with high-deductible plans—making safer alternatives more accessible and potentially reducing long-term reliance on opioids.
HealthcarePeopleRef: Sec. 1(1), Sec. 2(1), Sec. 3(1)The public education pamphlet could empower patients to engage in shared decision-making with providers, increasing use of non-drug therapies (e.g., physical therapy, cognitive behavioral therapy) that are cost-effective and low-risk—particularly beneficial for Medicaid recipients and underserved communities with limited access to such services.
HealthcarePeopleRef: Sec. 4May reduce state spending over time by lowering rates of opioid misuse, addiction, overdose, and associated emergency and long-term care costs—especially impactful for Medicaid and state employee health plans, which bear direct fiscal responsibility for these outcomes.
HealthcarePeopleRef: Sec. 1(1), Sec. 2(1), Sec. 3(1)Supports equity in pain management by preventing formulary discrimination against nonopioids—helping address disparities where patients of color and rural residents are disproportionately denied access to non-opioid options due to prior authorization hurdles or tiered formularies.
HealthcareLean peopleRef: Sec. 1(1), Sec. 2(1), Sec. 3(1)Encourages use of non-drug pain therapies (e.g., acupuncture, exercise programs) covered under some plans—potentially benefiting people with chronic pain conditions (e.g., arthritis, back pain) who struggle with long-term opioid use and its side effects.
HealthcareLean peopleRef: Sec. 1(1), Sec. 2(1), Sec. 3(1)
Potential Concerns (5)
Health plans may respond to the mandate by shifting coverage toward fewer nonopioid options overall (e.g., removing certain nonopioids from formularies) to avoid violating the ‘no more restrictive’ rule while still containing costs—potentially reducing patient choice in nonopioid alternatives, especially for complex or off-label uses.
HealthcareRef: Sec. 1(1)(b), Sec. 2(1)(b), Sec. 3(1)(b)The educational pamphlet may be underutilized by patients and providers due to lack of awareness, limited outreach, or low health literacy—limiting its real-world impact on treatment decisions despite its good intentions.
HealthcareRef: Sec. 4Health plans may increase copays or prior authorization for *all* pain medications (opioid and nonopioid alike) to offset compliance costs—potentially raising barriers for everyone, not just shifting burden to nonopioids.
HealthcareRef: Sec. 1(1), Sec. 2(1), Sec. 3(1)The prohibition on labeling nonopioids as ‘nonpreferred’ may conflict with clinical judgment—e.g., some nonopioids (e.g., NSAIDs) carry significant cardiovascular or GI risks for certain populations, and blanket equal coverage may delay safer, individualized care.
HealthcareRef: Sec. 1(1), Sec. 2(1), Sec. 3(1)The educational pamphlet lacks enforcement mechanisms or quality assurance—there is no requirement for evidence-based content review, translation, or accessibility accommodations, limiting its utility for non-English speakers, people with disabilities, or low-literacy populations.
HealthcareRef: Sec. 4
Who Is Most Affected
Low- and middle-income patients with chronic pain—especially those on Medicaid or high-deductible plans—will benefit most, as they face the highest out-of-pocket costs and administrative barriers to nonopioid drugs. The bill directly reduces financial and access barriers for this group.
While providers gain more flexibility to prescribe nonopioids without prior authorization hurdles, they may face increased administrative burden from navigating new coverage rules and potential pushback from PBMs. Overall, the net effect is positive for clinical autonomy and patient care.
Health insurers and PBMs will incur costs to restructure formularies and utilization management protocols. While they may pass some costs to employers or government payers, the mandate reduces their discretion to steer patients toward higher-margin opioids—making this group net losers in terms of operational control.
Medicaid-managed care organizations must comply with the same equal-coverage rules but operate on thin margins; they may reduce nonopioid coverage breadth to stay within budget, potentially limiting access for enrollees despite the mandate.
State employees and dependents benefit from improved access to nonopioid treatments under state health plans, but if insurers raise premiums to offset compliance costs, the net benefit is modest—especially for higher-income enrollees less sensitive to copays.